Moderna is committed to enhancing diversity in clinical trial participation. The goals are to enhance education about the role of clinical trials, increase awareness of clinical trials, expand diversity in clinical trials by reducing barriers to clinical trial access and participation, use real world data to enhance information on diverse populations, and increase information about diversity and inclusion in clinical trials. The commitment also includes how clinical trials are conducted to protect the rights, safety, and well-being of clinical trial participants. Today, research participants’ rights are protected by law and by ethics committees such as institutional review boards, or IRBs.
At the core of these principles Moderna is striving to better serve historically underserved populations. By diversifying clinical trial populations, we can better reflect the broad patient population that will use the new medicine once it is approved and improve health outcomes. It is with these core principles in mind that the Moderna commits to continuing to work with community groups, patients, patient advocacy groups, regulatory authorities, health care practitioners, academics, and policymakers to define the systematic and impactful approaches that can enhance the diversity of clinical trial participants and help reduce health care disparities.

During the post-approval phase, collecting clinical real-world data or evidence can be an important method of supplementing trial data, in compliance with all applicable local laws and regulations. These data can also serve as an effective and efficient means to enhancing understanding of drug effects in diverse patient populations. Enhancing Information About Diversity and Inclusion in Clinical Trial Participation. Lastly, to promote transparency and accountability, that we adopt these new principles commit to publicly sharing information about their policies and practices to increase clinical trial diversity.